近患者丙肝测定得到确证
|
By LabMedica International staff writers Posted on 03 Jun 2018 |
|
图片：Genedrive HCV ID试剂盒是一种定性测定，在去中心化的环境下运行，90分钟出结果（图片蒙Genedrive公司惠赐）。
丙肝病毒(HCV)的慢性感染是一种主要的公共卫生问题，据估计感染了世界1.0%的人口（7100万人），肝硬化和肝癌每年致死40万人。
一种手持式便携设备仅重600克左右，略大于21盎司，经过确证，可作为丙肝病毒的床旁分子诊断系统与测定产品。一项新研究用熔峰比率分析验证了对HCV病毒载量进行半定量评估这一概念。
来自多国的一组科学家与法国巴黎巴斯德研究所(www.pasteur.fr)的科学家合作，让四名操作员用三台仪器检验了130份临床血浆样本与血清样本。从多个非洲国家收集样本，包括加纳、肯尼亚、毛里求斯、莫桑比克、尼日利亚、南非、乌干达和津巴布韦，在雅培实验室(Abbott Park, IL, USA; www.molecular.abbott)的m2000上使用RealTime HCV Genotype II检验，这属于HCV常规诊断检验的一部分。
科研小组确证了英国曼彻斯特Genedrive公司(www.genedriveplc.com)的床旁(POC) HCV测定，检验过程分两步，先制备血浆或血清，再进行逆转录(RT)反应，用目标HCV RNA生成互补DNA (cDNA)。cDNA经过非对称聚合酶链反应(PCR)，生成单链产品的线性扩增，然后用一只次级杂交探针检测，再做解离曲线分析。
这款床旁测定产品识别出全部的HCV基因型，检测限为2,362 IU/毫升（95%置信区间为1966 - 2788）。选取422名HCV慢性感染患者与503名抗HCV抗体和HCV RNA阴性的对照者，Genedrive HCV测定的灵敏度为98.6%（95%置信区间为96.9% - 99.5%），特异性为100%（95%置信区间为99.3% - 100%）。此外，熔峰比率分析验证了HCV半定量评估的原理。在一个资源有限的国家的真实临床场合进一步确证了这项检验。
该研究的论文发表于2018年4月3日的《BMJ Gut》杂志。作者总结说，他们在真实临床场合证明了一个概念——Genedrive HCV测定非常有望为分布式HCV核酸扩增检验(NAAT)提供一台价格适中、性能可靠的仪器。这种高度灵敏特异的检验最近获得了CE-IVD认证，将能够在任何临床场合实时管理丙肝慢性感染患者的治疗。
巴斯德研究所>>> www.pasteur.fr
雅培实验室>>> www.molecular.abbott
Genedrive >>> www.genedriveplc.com
Gold Member
Collection and Transport System
PurSafe Plus®
Capillary Blood Collection Tube
IMPROMINI M3
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Latest 临床化学 News
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read more
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Technology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more